Publications by authors named "Carla Strina"

Claim this Profile
C
Comparative efficacy between real-world and randomized studies of palbociclib+endocrine therapy in HR-positive/HER2-negative metastatic breast cancer: systematic review and meta-analysis.
Francesco Schettini, Sabrina Nucera, Giuseppe Di Grazia, Fabiola Giudici, Carla Strina

JNCI Cancer Spectr· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Next-generation sequencing-based evaluation of the actionable landscape of genomic alterations in solid tumors: the "MOZART" prospective observational study.
Francesco Schettini, Marianna Sirico, Marco Loddo, Gareth H Williams, Keeda-Marie Hardisty, Carla Strina

Oncologist· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer.
Abul Azad, Maryam Arshad, Daniele Generali, Katharina Feldinger, Merel Gijsen, Carla Strina

Cancer Commun (Lond)· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessing the long-term prognostic ability of the 70 gene expression signature MammaPrint in an Italian single-center prospective cohort study of early-stage intermediate-risk breast cancer patients.
Daniele Generali, Andrea Rocca, Carla Strina, Manuela Milani, Enrico Fiorino

Heliyon· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of response to neoadjuvant chemotherapy by MammaTyper® across breast cancer subtypes: A retrospective cross-sectional study.
Francesco Schettini, Silvana Saracchini, Anna Bassini, Wally Marus, Serena Corsetti, Carla Strina

Breast· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Carla Strina

NPJ Breast Cancer· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paolo Fuso, Carla Strina

NPJ Breast Cancer· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Faecal microbiota composition is related to response to CDK4/6-inhibitors in metastatic breast cancer: A prospective cross-sectional exploratory study.
Francesco Schettini, Alessandra Fontana, Federica Gattazzo, Carla Strina, Manuela Milani

Eur J Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer.
Alessandra Fabi, Luisa Carbognin, Andrea Botticelli, Ida Paris, Paola Fuso, Carla Strina

NPJ Breast Cancer· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computational reactive-diffusive modeling for stratification and prognosis determination of patients with breast cancer receiving Olaparib.
Francesco Schettini, Maria Valeria De Bonis, Carla Strina, Manuela Milani, Nicoletta Ziglioli

Sci Rep· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum: Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Silvia P Corona, Fabiola Giudici, Guy Jerusalem, Eva Ciruelos, Carla Strina

Oncotarget· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
Alberto D'Angelo, Fabiola Giudici, Robert Chapman, Jacob Darlow, Huseyin Kilili, Carla Strina

Curr Issues Mol Biol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry.
Laia Garrigós, Cristina Saura, Clara Martinez-Vila, Alberto Zambelli, Mark Bower, Carla Strina

Ther Adv Med Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical, Radiometabolic and Immunologic Effects of Olaparib in Locally Advanced Triple Negative Breast Cancer: The OLTRE Window of Opportunity Trial.
Francesco Schettini, Silvia Paola Corona, Fabiola Giudici, Carla Strina, Marianna Sirico

Front Oncol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature.
Ottavia Bernocchi, Marianna Sirico, Silvia Paola Corona, Carla Strina, Manuela Milani

Pharmaceuticals (Basel)· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study.
Francesco Schettini, Navid Sobhani, Anna Ianza, Tiziana Triulzi, Alfredo Molteni, Carla Strina

Breast Cancer Res Treat· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Changes of the Standardized Uptake Values (SUV) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer.
Marianna Sirico, Ottavia Bernocchi, Navid Sobhani, Fabiola Giudici, Silvia P Corona, Carla Strina

Cancers (Basel)· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of BMI on the outcome of metastatic breast cancer patients treated with everolimus: a retrospective exploratory analysis of the BALLET study.
Silvia P Corona, Fabiola Giudici, Guy Jerusalem, Eva Ciruelos, Carla Strina

Oncotarget· June 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benefit of the addition of hormone therapy to neoadjuvant anthracycline-based chemotherapy for breast cancer: comparison of predicted and observed pCR.
Daniele Generali, Silvia Paola Corona, Lajos Pusztai, Roman Rouzier, Giovanni Allevi, Carla Strina

J Cancer Res Clin Oncol· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Could gonadotropin-releasing hormone analogs be helpful in the treatment of triple-negative breast cancer?
Silvia Paola Corona, Giandomenico Roviello, Carla Strina, Manuela Milani, Giovanni Allevi

Future Oncol· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hypoxia-related biological markers as predictors of epirubicin-based treatment responsiveness and resistance in locally advanced breast cancer.
Manuela Milani, Sergio Venturini, Simone Bonardi, Giovanni Allevi, Carla Strina

Oncotarget· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase II study of olaparib in breast cancer patients: biological evaluation from a 'window of opportunity' trial.
Giandomenico Roviello, Manuela Milani, Angela Gobbi, Martina Dester, Maria Rosa Cappelletti, Carla Strina

Future Oncol· October 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Phase Ib Open-Label Study to Assess the Safety and Tolerability of Everolimus in Combination With Eribulin in Triple-Negative Breast Cancers.
Giandomenico Roviello, Manuela Milani, Angela Gobbi, Maria Rosa Cappelletti, Laura Zanotti, Carla Strina

Clin Breast Cancer· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Treatment Approach: The Rosetta Stone for Breast Cancer?
Daniele Generali, Mara Ardine, Carla Strina, Manuela Milani, Maria Rosa Cappelletti

J Natl Cancer Inst Monogr· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Primary Letrozole Treatment on Tumor Expression of mTOR and HIF-1α and Relation to Clinical Response.
Daniele Generali, Alfredo Berruti, Maria Rosa Cappelletti, Laura Zanotti, Giulia Brugnoli, Carla Strina

J Natl Cancer Inst Monogr· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis